OmniCorder Technologies Adds New Sensor Technology Patent from California Institute of Technology.

Business Editors/Health/Medical Writers

EAST SETAUKET, N.Y.--(BUSINESS WIRE)--Dec. 29, 2003

OmniCorder Technologies (OTCBB - PMOS.OB) today announced the addition of a new infrared sensor patent to its growing portfolio of intellectual property. The patent entitled "Dual Band Focal Plane Array" was granted to scientists developing this new generation of QWIP (Quantum Well Infrared Photodetector) infrared sensors at NASA's Jet Propulsion Laboratory (JPL), Pasadena, CA and at the Army Research Laboratory (ARL), Adelphi, MD. The patent was assigned to the California Institute of Technology (Caltech). OmniCorder Technologies owns the exclusive world-wide rights to this and other infrared sensor patents, for biomedical applications, through a license agreement with Caltech. QWIP sensor technology is used in the BioScanIR(R) System, the company's medical imaging product.

Commenting on the news, Mark A. Fauci, OmniCorder Technologies' President and Chief Executive Officer, said, "This patent represents another important advance in the company's core sensor technology, which is being developed for future versions of the BioScanIR(R) System. It promises to be a very valuable addition to our growing portfolio of intellectual property."

The further development of high performance multi-band infrared sensors has been one of the central components in the company's research and development efforts. On October 27, 2003, the company announced that it was awarded a contract from the Department of Defense's Missile Defense Agency (MDA) to develop a four-band QWIP infrared sensor. QWIP technology was originally developed by the scientists at JPL. OmniCorder is collaborating with these same scientists at both JPL and ARL on this most recent project. Multi-band infrared sensors have a number of unique capabilities which will make many powerful medical imaging applications possible. These include complex, real-time, in vivo analysis of gases, fluids and other diagnostically important characteristics of living tissue.

About The BioScanIR(R) System

The Company's BioScanIR(R) System, which is available commercially in the U.S. and Europe, detects diseases that affect changes in blood perfusion by detecting minute changes in the pattern of infrared photon emissions over time. The detector technology used in the system, known as a Quantum Well Infrared Photodetector (QWIP), was originally developed for the department of Defense's Ballistic Missile Defense Initiative. The Company owns an exclusive, worldwide license to use the technology for biomedical applications. OmniCorder believes that the BioScanIR(R) System will improve disease detection and disease management capabilities in many vascular and cancer medical applications. Both cancer and vascular disease are associated with abnormal blood flow in tissues and organs.

About OmniCorder Technologies

OmniCorder Technologies is headquartered in East Setauket, NY. OmniCorder is a leading developer of medical imaging applications using advanced infrared focal plane arrays. OmniCorder provides imaging technology for clinicians and researchers for drug discovery, disease detection and disease management applications. The Company recently announced a $7.8 million funding coinciding with a reverse acquisition and public trading of shares, which are quoted on the Over-the-Counter (OTC) Bulletin Board under the symbol PMOS.OB.

OmniCorder's mission is to improve the quality and cost-effectiveness of healthcare services and research through identifying, acquiring and adapting military and aerospace technology for biomedical applications.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, the ability of the Company to develop effective new products and receive governmental approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.